Hani Hassoun
YOU?
Author Swipe
View article: Data from Immune MRD Status Informs Tumor MRD Outcome Prognostication in Patients with Multiple Myeloma on Lenalidomide Maintenance
Data from Immune MRD Status Informs Tumor MRD Outcome Prognostication in Patients with Multiple Myeloma on Lenalidomide Maintenance Open
Purpose:Lenalidomide (Len) maintenance is the most frequently utilized approach for newly diagnosed patients with multiple myeloma following induction therapy with/without consolidative high-dose melphalan and autologous stem cell transpla…
View article: Supplementary Data2 from Immune MRD Status Informs Tumor MRD Outcome Prognostication in Patients with Multiple Myeloma on Lenalidomide Maintenance
Supplementary Data2 from Immune MRD Status Informs Tumor MRD Outcome Prognostication in Patients with Multiple Myeloma on Lenalidomide Maintenance Open
Trial protocol
View article: Supplementary Data1 from Immune MRD Status Informs Tumor MRD Outcome Prognostication in Patients with Multiple Myeloma on Lenalidomide Maintenance
Supplementary Data1 from Immune MRD Status Informs Tumor MRD Outcome Prognostication in Patients with Multiple Myeloma on Lenalidomide Maintenance Open
Revised supplement
View article: Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma
Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma Open
View article: Correction: Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma
Correction: Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma Open
View article: Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma
Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma Open
View article: Practical use of talquetamab in relapsed/refractory multiple myeloma: the Memorial Sloan Kettering Cancer Center experience
Practical use of talquetamab in relapsed/refractory multiple myeloma: the Memorial Sloan Kettering Cancer Center experience Open
View article: Outcomes in frail patients receiving BCMA-directed bispecific antibodies for relapsed/refractory multiple myeloma
Outcomes in frail patients receiving BCMA-directed bispecific antibodies for relapsed/refractory multiple myeloma Open
Patients with relapsed/refractory (R/R) multiple myeloma (MM) are often frail with preexisting comorbidities and poor performance status (PS). To evaluate clinical characteristics and outcomes based on frailty, we conducted a single-center…
View article: A High-Fiber Plant-Based Intervention in Precursor Plasma Cell Disorders Improves Dietary Quality and Microbiome
A High-Fiber Plant-Based Intervention in Precursor Plasma Cell Disorders Improves Dietary Quality and Microbiome Open
View article: Belantamab mafodotin in patients with relapsed/refractory multiple myeloma: a real-world experience
Belantamab mafodotin in patients with relapsed/refractory multiple myeloma: a real-world experience Open
View article: Restarting teclistamab and talquetamab after prolonged dose delay may not require re–step-up dosing
Restarting teclistamab and talquetamab after prolonged dose delay may not require re–step-up dosing Open
View article: Introduction to Radiological Physics and Radiation Dosimetry
Introduction to Radiological Physics and Radiation Dosimetry Open
View article: Evaluating serum free light chain ratio as a biomarker in multiple myeloma
Evaluating serum free light chain ratio as a biomarker in multiple myeloma Open
Not available.
View article: Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma
Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma Open
View article: Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes
Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes Open
Multiple myeloma is a treatable, but currently incurable, hematological malignancy of plasma cells characterized by diverse and complex tumor genetics for which precision medicine approaches to treatment are lacking. The Multiple Myeloma R…
View article: Supplementary Data TS1-4 from Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets
Supplementary Data TS1-4 from Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets Open
Supplementary Table S1-S4
View article: Supplementary fig 1 from Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets
Supplementary fig 1 from Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets Open
Supplementary Figure S1. Volcano plot showing the difference in the relative abundance of butyrate producers between sustained MRD negative and MRD positive/non-sustained MRD negative.
View article: Supplementary fig 1 from Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets
Supplementary fig 1 from Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets Open
Supplementary Figure S1. Volcano plot showing the difference in the relative abundance of butyrate producers between sustained MRD negative and MRD positive/non-sustained MRD negative.
View article: Supplementary Data TS1-4 from Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets
Supplementary Data TS1-4 from Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets Open
Supplementary Table S1-S4
View article: Patients’ Perceptions, Experiences, and Feedback on a Pilot Plant-Based Dietary Intervention: A Qualitative Survey
Patients’ Perceptions, Experiences, and Feedback on a Pilot Plant-Based Dietary Intervention: A Qualitative Survey Open
Objectives: Providing patient-centered care for those undergoing a dietary intervention is critical in improving outcomes. Our objectives were to understand the perception, experiences, and post-intervention plans of those who completed ou…
View article: Colesevelam for Lenalidomide Associated Diarrhea in Patients with Multiple Myeloma
Colesevelam for Lenalidomide Associated Diarrhea in Patients with Multiple Myeloma Open
Lenalidomide maintenance is associated with a significantly improved progression-free in patients with newly diagnosed multiple myeloma. Maintenance with lenalidomide is generally well tolerated; however, lenalidomide associated diarrhea i…
View article: Comparison of infectious complications with BCMA-directed therapies in multiple myeloma
Comparison of infectious complications with BCMA-directed therapies in multiple myeloma Open
B-cell-maturation-antigen (BCMA)-directed therapies are highly active for multiple myeloma, but infections are emerging as a major challenge. In this retrospective, single-center analysis we evaluated infectious complications after BCMA-ta…
View article: Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma
Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma Open
Despite being the mainstay of management for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), there is limited data regarding the impact of tocilizumab (TCZ) and corticosteroids (CCS) on c…
View article: Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma
Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma Open
B-cell maturation antigen (BCMA)–targeting therapeutics have dramatically improved outcomes in relapsed/refractory multiple myeloma (RRMM). However, whether the mechanisms of resistance between these therapies are shared and how the identi…
View article: Unscheduled health care interactions in patients with multiple myeloma receiving T-cell redirection therapies
Unscheduled health care interactions in patients with multiple myeloma receiving T-cell redirection therapies Open
Outcomes for patients with relapsed/refractory multiple myeloma (R/RMM) have dramatically improved after the development and now growing utilization of B-cell maturation antigen–targeted chimeric antigen receptor (CAR) T-cell therapy and b…
View article: Patterns of CRS with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapy
Patterns of CRS with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapy Open
Teclistamab (Tec) is a first-in-class BCMA × CD3 bispecific T-cell engager antibody approved for treating multiple myeloma progressing after at least 4 lines of therapy. The objective of this study was to evaluate the rate of cytokine rele…
View article: Comparison of Infectious Complications with BCMA-directed Therapies in Multiple Myeloma
Comparison of Infectious Complications with BCMA-directed Therapies in Multiple Myeloma Open
B-cell-maturation-antigen (BCMA)-directed therapies are highly active for multiple myeloma, but infections are emerging as a major challenge. In this retrospective, single-center analysis we evaluated infectious complications after BCMA-ta…
View article: Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens
Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens Open
View article: CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma
CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma Open
Teclistamab, a B-cell maturation antigen (BCMA)- and CD3–targeting bispecific antibody, is an effective novel treatment for relapsed/refractory multiple myeloma (R/RMM), but efficacy in patients exposed to BCMA-directed therapies and mecha…
View article: Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups
Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups Open
Multiple myeloma (MM) is twice as common in Black individuals compared with in White individuals, and diabetes mellitus (DM) disproportionately affects Black patients. Although numerous studies have shown a correlation between DM and MM, t…